StopAfib interviews Dr. James Reiffel Find a transcript and more on Dr. Reiffel at: www.stopafib.org In this video interview at Heart Rhythm 2012, Dr. James Reiffel updates us on new directions in drug treatments for atrial fibrillation. He talks about the combination of ranolazine (Ranexa) and dronedarone (Multaq), both used …
Read MoreArchives
At Heart Rhythm 2012, Dr. James Reiffel gave us an update on new medications for treating atrial fibrillation, including the combination of low doses of ranolazine (Ranexa) and dronedarone (Multaq). He also talked about rate control vs. rhythm control for afib, and how the decision can vary by age and level of symptoms. Watch the …
Read MoreAs a patient, you probably see lots of hype-filled reports about various drugs. After a drug is approved, there’s an inevitable blitz of negative publicity which often scares people away from important new solutions that could help them. There has been so much news lately about Multaq (dronedarone), the drug designed to provide the benefits …
Read MoreStopAfib.org interviews Dr. Peter Kowey See the full transcript at: www.stopafib.org In this video interview at Boston Atrial Fibrillation Symposium 2010, Dr. Peter Kowey talked about a number of exciting new things in the atrial fibrillation world, including the Cabana clinical trials, the Safari catheter ablation registry, dronedarone as a …
Read MoreIn this video interview at Boston Atrial Fibrillation Symposium, Dr. Peter Kowey, President of the Main Line Health Heart Center, talked about a number of exciting new things in the atrial fibrillation world. His topics included the Cabana clinical trials, the Safari catheter ablation registry, dronedarone as a replacement for amiodarone, atrial selective drugs, and …
Read MoreIn this video from Boston Atrial Fibrillation Symposium 2010, Professor John Camm discusses the two newest antiarrhythmic drugs, dronedarone (Multaq®), which is now approved in the US and Europe for atrial fibrillation, and vernakalant, which is a year or two away. These antiarrhythmic (rhythm control) drugs help to put patients …
Read MoreThe Atrial Fibrillation Association in the UK was shocked by the decision by the National Institute for Health and Clinical Excellence (NICE) to deny atrial fibrillation patients access to dronedarone, a medication that has been approved in the U.S. and Europe. AFA is conducting a campaign to make the voices of atrial fibrillation patients heard. …
Read MoreAt Boston Atrial Fibrillation Symposium 2010, Prof. John Camm talked about the two newest antiarrhythmic drugs for atrial fibrillation treatment, dronedarone (Multaq®) and vernakalant. These antiarrhythmic (rhythm control) drugs help to put patients back into normal sinus rhythm, or to keep them in it. See the video: Interview with Professor John Camm at Boston Atrial …
Read MoreWe hear from so many afib patients every day about the trials, tribulations, and fears regarding being on amiodarone, or their refusal to take it. Since the FDA approved Multaq® (dronedarone) recently, the most frequent question I've fielded has been "When will Multaq® be available?" That happened this week, and the excitement they have shared …
Read MoreBREAKING NEWS Multaq(R), the much anticipated replacement for amiodarone, just received FDA approval. Read the press release: FDA Approves Multaq® for Patients with Atrial Fibrillation or Atrial Flutter
Read More